The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Aβ and Tau Toxicities in Alzheimer's Are Linked via Oxidative Stress-Induced P38 Activation: Protective Role of Vitamin E
Open accessAbstract
Oxidative stress is a hallmark of Alzheimer's disease (AD). We propose that rather than causing damage because of the action of free radicals, oxidative stress deranges signaling pathways leading to tau hyperphosphorylation, a hallmark of the disease. Indeed, incubation of neurons in culture with 5 µM beta-amyloid peptide (Aβ) causes an activation of p38 MAPK (p38) that leads to tau hyperphosphorylation. Inhibition of p38 prevents Aβ-induced tau phosphorylation. Aβ-induced effects are prevented when neurons are co-incubated with trolox (the water-soluble analog of vitamin E). We have confirmed these results in vivo, in APP/PS1 double transgenic mice of AD. We have found that APP/PS1 transgenic mice exhibit a high level of P-p38 in the hippocampus but not in cortex and this is prevented by feeding animals with a diet supplemented with vitamin E. Our results underpin the role of oxidative stress in the altered cell signaling in AD pathology and suggest that antioxidant prevention may be useful in AD therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, it has been reported that the Aβ-induced oxidative stress leads to the activation of p38 MAPK and subsequent tau hyperphosphorylation (Giraldo et al., 2014).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Giraldo et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,369
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G. W., Robinson, F. L., Gibson, T. B., Xu, B.-E., Karandikar, M. S., Berman, K. S., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,111
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Pearson, R. C., Esiri, M. M., Hiorns, R. W., Wilcock, G. K., & Powell, T. P. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4531 · Cited by 987 · cited 1×
“Some structures like the hippocampus are very heavily damaged whereas others, like the motor, somatic sensory, and primary visual areas are spared [17].”
BackgroundDysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G. D., McCarten, J. R., Malphurs, J., et al. (2014) · JAMA · doi:10.1001/jama.2013.282834 · Cited by 628
Alzheimer's disease – do tauists and baptists finally shake hands?
Mudher, A. K., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 523
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D. J., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 424
p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis
Dolado, I., Swat, A., Ajenjo, N., Vita, G. D., Cuadrado, A., & Nebreda, Á. R. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.013 · Cited by 422
Zhu, X., Rottkamp, C. A., Boux, H., Takeda, A., Perry, G., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.10.880 · Cited by 378
p38 Kinase Is Activated in the Alzheimer's Disease Brain
Hensley, K., Floyd, R. A., Zheng, N., Nael, R., Robinson, K. A., Nguyen, X., Pye, Q. N., Stewart, C. A., Geddes, J., Markesbery, W. R., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722053.x · Cited by 373 · cited 1×
“In Alzheimer’s disease (AD), increased p38 MAPK activity in human brains was observed more than a decade ago [2].”
BackgroundThe many paths to p38 mitogen-activated protein kinase activation in the immune system
Ashwell, J. D. (2006) · Nature reviews. Immunology · doi:10.1038/nri1865 · Cited by 370 · cited 1×
“The p38 MAPK is a 38 kD polypeptide with 4 isoforms (α, β, γ, δ) all of which are activated by dual phosphorylation at Thr180 and Tyr182 residues [1].”
BackgroundMitochondria dysfunction of Alzheimer's disease cybrids enhances Aβ toxicity
Cardoso, S. M., Santana, I. J., Swerdlow, R. H., & Oliveira, C. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02438.x · Cited by 262
Lloret, A., Badía, M.-C., Mora, N. J., Pallardó, F. V., Alonso, M.-D., & Viña, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1033 · Cited by 225 · cited 3×
“The paradox of vitamin E is that it is efficient for some patients, but not for others [22].”
BackgroundInfluentialP38 MAP kinase is activated at early stages in Alzheimer's disease brain
Sun, A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00180-8 · Cited by 219 · cited 1×
“Post-mortem brains of AD patients revealed that phospho-p38 MAPK immune reactivity occurs at a very early stage of the disease [3,4].”
BackgroundSheng, J. G., Jones, R. A., Zhou, X. Q., McGinness, J. M., Van Eldik, L. J., Mrak, R. E., & Griffin, W. S. T. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00041-9 · Cited by 176 · cited 1×
“We propose that rather than causing damage because of the action of free radicals, oxidative stress deranges signaling pathways leading to tau hyperphosphorylation, a hallmark of the disease.”
BackgroundPei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3107 · Cited by 165
Amyloid-β Toxicity and Tau Hyperphosphorylation are Linked Via RCAN1 in Alzheimer's Disease
Lloret, A., Badía, M.-C., Giraldo, E., Ermak, G., Alonso, M.-D., Pallardó, F. V., Davies, K. J. A., & Viña, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110890 · Cited by 133 · cited 1×
“We described a role of the oxidative stress-induced upregulation of RCAN1 in AD [16].”
BackgroundFeijoo, C., Campbell, D. G., Jakes, R., Goedert, M., & Cuenda, A. (2005) · Journal of Cell Science · doi:10.1242/jcs.01655 · Cited by 133 · cited 1×
“We propose that rather than causing damage because of the action of free radicals, oxidative stress deranges signaling pathways leading to tau hyperphosphorylation, a hallmark of the disease.”
BackgroundVitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Isaac, M. G. E. K. N., Clark, A. R., Rusted, J. M., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub3 · Cited by 125 · cited 1×
“However there are a number of studies questioning the efficacy of vitamin E treatment [20,21].”
BackgroundErmak, G., Harris, C. D., & Davies, K. J. A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0846com · Cited by 121
Butterfield, D. A., Yatin, S. M., Varadarajan, S., & Koppal, T. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)09050-3 · Cited by 99
Vitamin E for Alzheimer's disease and mild cognitive impairment
Isaac, M. G. E. K. N., Quinn, R., & Tabet, N. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854 · Cited by 96 · cited 1×
“However there are a number of studies questioning the efficacy of vitamin E treatment [20,21].”
BackgroundYoshida, H., & Goedert, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04052.x · Cited by 83
Kinase activities increase during the development of tauopathy in htau mice
Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., & Noble, W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04930.x · Cited by 78 · cited 1×
“Studies using transgenic mice exhibiting hyperphosphorylated tau also show positive correlation between phosphorylated (activated) p38 and the level of aggregated tau [9].”
BackgroundBozaykut, P., Karademir-Yilmaz, B., Yazgan, B., Sözen, E., Siow, R. C. M., Mann, G. E., & Özer, N. K. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.02.017 · Cited by 75 · cited 1×
“Recently it has been shown a significant increase in mRNA levels of the scavenger receptor CD36 in aortae of cholesterol fed rabbits and shown that vitamin E treatment attenuated increased CD36 mRNA expression [23].”
BackgroundGender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease
Lloret, A., Badía, M.-C., Mora, N. J., Ortega, Á., Pallardó, F. V., Alonso, M.-D., Atamna, H., & Viña, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.017 · Cited by 60 · cited 2×
“We previously established that Aβ produces free radicals by binding to heme which interferes with the respiratory chain and subsequently increases peroxide production in mitochondria [10].”
BackgroundTesta, G., Gamba, P., Scipio, F. D., Sprio, A. E., Salamone, P., Gargiulo, S., Sottero, B., Biasi, F., Berta, G. N., Poli, G., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.08.581 · Cited by 18
Vitamin E for Alzheimer's disease?
Simonson, W. (2014) · Geriatric Nursing · doi:10.1016/j.gerinurse.2014.02.003 · Cited by 16
Vitamin E for Alzheimer's disease
Tabet, N., Birks, J., Evans, J. G., Orrell, M., & Spector, A. (2000) · UCL Discovery (University College London) · Cited by 15
Flagged first, then by citations
Cited by
Sorted by citations
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
“In AD and PD, Aβ would cause an activation of p38 MAPK in cell that leads to the abnormal phosphorylation of Tau [17].”
BackgroundInfluentialCompromised MAPK signaling in human diseases: an update
Kim, E., & Choi, E. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,033
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2525967 · Cited by 810
“An abnormal accumulation of hyperphosphorylated tau proteins can lead to intracellular NFT formation (Figure 1) [41, 42].”
BackgroundUnderstanding mechanisms of antioxidant action in health and disease
Halliwell, B. B. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 709
“…increased oxidative damage arises both from increased ROS production by several mechanisms (including generation of ROS by β-amyloid and inappropriate activation of microglia (brain phagocytes)) 156,157,160–162 and from impaired clearance of damaged molecules, especially oxidized proteins 16,17 .”
Jiang, T., Sun, Q., & Chen, S. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.005 · Cited by 605
“Pearson and colleagues reported in vivo evidence that OS increased the level of p-tau and induced the p38 MAPK pathway (Giraldo et al., 2014).”
Background
Metadata
- Authors
- Giraldo, E., Lloret, A., Fuchsberger, T., & Viña, J.
- Affiliations
- Universitat de València (ES)
- Corresponding author
- Viña, J.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2014
- Volume
- 2
- Pages
- 873-877
- ISSN
- 2213-2317 (ISSN-L)
- PMC
- PMC4099506
- OpenAlex
- W2039173359
- Cited by
- 268
- References
- 28
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 23 · 2023: 34 · 2022: 27 · 2021: 26 · 2020: 27 · 2019: 24 · 2018: 22 · 2017: 21 · 2016: 12 · 2015: 19 · 2014: 3
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Redox Biology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Spanish Ministry of Education and Science (MEC) (SAF2010-19498)
- “Red Tematica de investigacion cooperativa en envejecimiento y fragilidad” (RETICEF) (ISCIII2006-RED13-027, ISCIII2012-RED-43-029)
- “Conselleria d’Educació, Cultura i Esport de la Generalitat Valenciana” (PROMETEO2010/074)
- “Fundació Gent Per Gent de la Comunitat Valenciana” (35NEURO)
- INCLIVA (RS2012-609)
- EU (CM1001, FRAILOMIC-HEALTH.2012.2.1.1-2)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Keywords
- Alzheimer's disease, amyloid-beta, tau hyperphosphorylation, oxidative stress, p38 MAPK, vitamin E, Trolox, APP/PS1 mice, hippocampus, antioxidant therapy, neuronal signaling
- MeSH terms
- Alzheimer Disease, Animals, Cells, Cultured, Disease Models, Animal, Hippocampus, Male, Mice, Transgenic, Neurons, Phosphorylation, Vitamin E, Amyloid beta-Peptides, tau Proteins, Oxidative Stress, Protective Agents, p38 Mitogen-Activated Protein Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
